Balaji Amines Q3 FY26: Revenue ₹331.30 Cr, PAT ₹30.76 Cr
Q3 FY26 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹331Cr
- +5.8% YoY
- −2.9% QoQ
- Net profit
- ₹31Cr
- 0% YoY
- −16.2% QoQ
- Margin
- 17%
- +2 pp YoY
- −1 pp QoQ
Guidance rank: #26 of 70 in Chemicals & Petrochemicals
See the sector's top 10 — free with your mobile number.
Based on Balaji Amines Ltd's Q3 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Revenue from Operations for Q3FY26: ₹331.30 crore, compared to ₹320.59 crore in Q3FY25 (consolidated) and ₹304.68 crore in Q3FY25 (standalone). EBITDA for Q3FY26 (Consolidated): ₹61.67 crore, up 15.12% YoY from ₹53.57 crore in Q3FY25
From Balaji Amines Ltd's Q3 FY26 earnings-call transcript · updated 25 Sept 2026.
Revenue & Sales Performance
- Revenue from Operations for Q3FY26: ₹331.30 crore, compared to ₹320.59 crore in Q3FY25 (consolidated) and ₹304.68 crore in Q3FY25 (standalone).
- Consolidated Q3FY26 Revenue growth YoY: 4.90%.
- Standalone Q3FY26 Revenue growth YoY: 0.62%.
- Total volumes for Q3FY26: 25,894 MT vs. 24,097 MT in Q3FY25.
- Amines volumes Q3FY26: 6,993 MT.
- Amines Derivatives volumes Q3FY26: 9,223 MT.
- Specialty Chemicals volumes Q3FY26: 9,678 MT.
2 more points from Balaji Amines Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Balaji Amines Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Unit 4 Greenfield Capex Phases 2 & 3 to be completed by FY 2027, including increased capacity utilization.
- Dimethyl Ether (DME) plant of 100,000 TPA capacity under Phase 3 expansion; under erection; commissioning expected FY 2026-27.
- N-Methyl Morpholine (NMM) 5,000 TPA manufacturing facility under execution; commissioning expected FY 2026-27.
- PG Pharma Grade facility under execution; commissioning expected FY 2026-27.
- Acetonitrile (ACN) improved process plant under execution; commissioning expected FY 2026-27.
- Methylamines capacity expanded from 48,000 TPA to 88,000 TPA; latest tech plant commissioned Nov 10, 2024.
2 more points from Balaji Amines Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Balaji Amines Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Balaji Amines Ltd said on order book & pipeline — free account, 30 seconds.
Balaji Amines Ltd — Quarterly revenue & net profit
Balaji Amines Ltd Q3 FY26 results — key figures
| ₹ Cr | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 331 | 313 | +5.8% | 341 | -2.9% |
| Operating profit (EBITDA) | 57 | 46 | +23.9% | 60 | -5% |
| Operating margin | 17% | 15% | +2 pp | 18% | -1 pp |
| Profit before tax | 46 | 41 | +12.2% | 52 | -11.5% |
| Net profit (PAT) | 31 | 31 | 0% | 37 | -16.2% |
| EPS (₹) | 9.70 | 10.24 | -5.3% | 10.67 | -9.1% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹468 Cr, net profit ₹67 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Balaji Amines's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Neochem Bio (Q3 FY26)
Revenue for Q2 FY26 (Sept’25) stood at ₹4,583.16 Lakh. Key investor presentation takeaways from Neochem Bio Solutions Ltd's Q3 FY26 investor presentation — and
- Thirumalai Chemicals (Q3 FY26)
Q3 FY26 Revenue from Operations (INR Cr):** . Key investor presentation takeaways from Thirumalai Chemicals Ltd's Q3 FY26 investor presentation — and how it ran
- IVP (Q3 FY26)
Q3 FY26 Revenue from Operations: ₹144.97 crore . Key investor presentation takeaways from IVP's Q3 FY26 investor presentation — and how it ranks against sector
- Gujarat Alkalies (Q3 FY26)
3,144.48 Crores, down from Rs. Key investor presentation takeaways from Gujarat Alkalies & Chemicals Ltd's Q3 FY26 investor presentation — and how it ranks agai
Potential multibaggers · Q2 FY27
Potential multibaggers in Chemicals & Petrochemicals
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Balaji Amines Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Balaji Amines Ltd Q3 FY26 results?
Revenue from Operations for Q3FY26: ₹331.30 crore, compared to ₹320.59 crore in Q3FY25 (consolidated) and ₹304.68 crore in Q3FY25 (standalone). EBITDA for Q3FY26 (Consolidated): ₹61.67 crore, up 15.12% YoY from ₹53.57 crore in Q3FY25
What is Balaji Amines Ltd share price analysis?
Balaji Amines Ltd currently shows a neutral. The stock trades at a P/E of 34.5 with a market cap of ₹7,036 Cr. Investors should review the full earnings analysis for detailed insights.
Is Balaji Amines Ltd planning capital expenditure?
Unit 4 Greenfield Capex Phases 2 & 3 to be completed by FY 2027, including increased capacity utilization.
Keep Balaji Amines Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
